← SynDRA
MAVELERTINIB
SynDRA canonical compound SYN0039189 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | EGFR |
|---|
| Mechanism of action | EGFR inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
Cross-references
Synonyms
- Egfr t790m inhibitor pf-06747775
- PF-06747775
- JYIUNVOCEFIUIU-RRKGBCIJSA-N
- PF06747775
- SCHEMBL20274518
- BCP17532
- PF 06747775
- Mavelertinib [USAN]
- YXX2180047
- Egfr T790M inhibitor PF-06747775
- MAVELERTINIB [INN]
- MAVELERTINIB [WHO-DD]
- compound 21 [PMID: 28287730]
- compound 21 (PMID: 28287730)
- mavelertinibum
- RefChem:810669
- UNII-YXX2180047
- Mavelertinib (USAN/INN)
- GTPL9765
- orb1705133
- SCHEMBL16714537
- SCHEMBL29377591
- JYIUNVOCEFIUIU-GHMZBOCLSA-N
- EX-A4999
- BDBM50450870
- NSC788365
- AKOS032945529
- EBC-498137
- NSC-788365
- AC-33593
- DA-66623
- HY-12972
- MS-27202
- CS-0012907
- C92352
- D11368
- T21322
- PF-06747775, >=98% (HPLC)
Look up MAVELERTINIB in the interactive SynDRA portal →